Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
As a GLP-1 receptor agonist, retatrutide may carry similar risks to semaglutide , which include: Acute pancreatitis Diabetic retinopathy complications (diabetes-related vision changes) Hypoglycemia (low blood sugar), especially when used with insulin Kidney or gallbladder issues Severe gastrointestinal reactions Allergic reactions Pulmonary aspiration during general anesthesia or deep sedation All GLP-1 receptor agonists carry a boxed warning for thyroid tumors based on animal studies
This 0.25 mg dosage is intended for treatment initiation and does not provide significant glycemic control
Retatrutide is a new drug being investigated for obesity and type 2 diabetes
| 23andMe
Directions:Apply evenly 2x a day, morning and evening
Latisse is a
US$ 28.37
US$ 21.55
US$ 22.51
